ROIV
What one share of Roivant Sciences holds
Pharmaceutical Preparations
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter.
Roivant Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.38 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.17 |
| Cash and investments | $5.32 |
| Book value | $5.86 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.04 | −$1.28 | $0.01 | −$0.89 | — | $2.76 |
| 2022 | $0.08 | −$1.26 | $0.03 | −$1.04 | — | $2.38 |
| 2023 | $0.04 | −$1.42 | $0.02 | −$1.20 | — | $1.52 |
| 2024 | $0.04 | $5.23 | $0.00 | −$0.92 | — | $7.40 |
| 2025 | $0.04 | −$0.24 | $0.01 | −$1.16 | — | $6.74 |
| 2026 | $0.01 | −$0.54 | $0.01 | −$1.09 | — | $6.28 |